|
|
Volumn 13, Issue 1 PART I, 1998, Pages 35-49
|
|
Economic aspects of antibacterial adverse effects
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMIKACIN;
AMINOGLYCOSIDE ANTIBIOTIC AGENT;
AMPICILLIN;
ANTIINFECTIVE AGENT;
AZTREONAM;
BETA LACTAM ANTIBIOTIC;
CARBENICILLIN;
CEPHALOSPORIN DERIVATIVE;
CIPROFLOXACIN;
CLOXACILLIN;
DIRITHROMYCIN;
ENOXACIN;
GENTAMICIN;
LEVOFLOXACIN;
MACROLIDE;
OFLOXACIN;
OXACILLIN;
PENICILLIN DERIVATIVE;
QUINOLINE DERIVED ANTIINFECTIVE AGENT;
ROXITHROMYCIN;
TEICOPLANIN;
TOBRAMYCIN;
VANCOMYCIN;
ADVERSE DRUG REACTION;
ANAPHYLAXIS;
ANTIBIOTIC THERAPY;
ARTHROPATHY;
COST;
COST EFFECTIVENESS ANALYSIS;
DIARRHEA;
DRUG HYPERSENSITIVITY;
ECONOMIC ASPECT;
GASTROINTESTINAL TOXICITY;
HEMOLYSIS;
HUMAN;
HYPOPROTHROMBINEMIA;
LIVER TOXICITY;
NEPHROTOXICITY;
NEUROTOXICITY;
OTOTOXICITY;
PENICILLIN ALLERGY;
PHLEBITIS;
PRIORITY JOURNAL;
QUALITY OF LIFE;
REVIEW;
SKIN TOXICITY;
THROMBOCYTE DYSFUNCTION;
TREATMENT FAILURE;
AMINOGLYCOSIDES;
ANTI-BACTERIAL AGENTS;
ANTI-INFECTIVE AGENTS;
ECONOMICS, PHARMACEUTICAL;
FLUOROQUINOLONES;
HUMANS;
LACTAMS;
MACROLIDES;
VANCOMYCIN;
|
|
EID: 0031962134
PISSN: 11707690
EISSN: None
Source Type: Journal
DOI: 10.2165/00019053-199813010-00004 Document Type: Article |
|
Times cited : (49)
|
|
References (1)
|
